Scinai Immunotherapeutics (SCNI) Asset Utilization Ratio (2026)

Scinai Immunotherapeutics (SCNI) reported Asset Utilization Ratio of 0.1 for Q1 2026.

Scinai Immunotherapeutics (SCNI) Asset Utilization Ratio (2026) Analysis & Trends

Scinai Immunotherapeutics (SCNI) has 1 years of Asset Utilization Ratio data on file, last reported at 0.1 in Q1 2026.

For the quarter ending Q1 2026, Asset Utilization Ratio changed N/A year-over-year to 0.1; the trailing twelve-month figure through Mar 2026 stood at 0.1 (changed N/A YoY), and the FY2025 full-year result was 0.19, up 347.72% from the prior year.
Asset Utilization Ratio steadied at 0.1 in Q1 2026.
In the past five years, Asset Utilization Ratio ranged from a high of 0.1 in Q1 2026 to a low of 0.1 in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.69
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.37
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Scinai Immunotherapeutics	352,860.00	-3.11 Bn	-1.12 Mn	0.10

Historic Data

Download Data

Date	Value
Mar 31, 2026	0.10